Boston Scientific device outperforms warfarin in A-fib study

05/10/2013 | MassDevice.com (Boston)

Boston Scientific's Watchman device proved more effective and safer in treating patients with atrial fibrillation than the anticoagulant drug warfarin, according to a 707-participant study. The study showed Watchman was superior to warfarin "for the combined endpoint of all stroke, cardiovascular or unexplained death and systemic embolism," the company said.

View Full Article in:

MassDevice.com (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health